{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:31:21Z","timestamp":1773869481798,"version":"3.50.1"},"reference-count":73,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,4,16]]},"DOI":"10.1080\/10428194.2024.2447371","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T17:53:08Z","timestamp":1736099588000},"page":"818-829","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review"],"prefix":"10.1080","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-2135","authenticated-orcid":false,"given":"Efrat","family":"Luttwak","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,1,5]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00155-6"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0075"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5083"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008119"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00400"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009855"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2856"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds429"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-013193"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00843"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)14110-4"},{"key":"e_1_3_1_20_1","unstructured":"NCCN guidelines. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell_blocks.pdf."},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.121"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30102-5"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_3_1_26_1","article-title":"Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study","author":"Barraclough A","year":"2020","unstructured":"Barraclough A, Agrawal S, Talaulikar D, et\u00a0al. Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica. 2020;","journal-title":"Haematologica"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003805.pub2"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002858"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3128"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149613"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100549"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01097"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01797"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184883"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00838"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05306-2"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7163"},{"key":"e_1_3_1_46_1","first-page":"484","article-title":"Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an Analysis from the BRIGHT Trial","volume":"130","author":"Kahl BS","year":"2017","unstructured":"Kahl BS, Burke JM, van der Jagt R, et\u00a0al. Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an Analysis from the BRIGHT Trial. Blood. 2017;130:484.","journal-title":"Blood"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15720"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013526"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-567958"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3253"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130208"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013073"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt562"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30618-1"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70008-0"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01234"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34810"},{"key":"e_1_3_1_60_1","unstructured":"European Commission approves Roche\u2019s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma. https:\/\/www.globenewswire.com\/news-release\/2022\/06\/08\/2458330\/0\/en\/European-Commission-approves-Roche-s-first-in-class-bispecific-antibody-Lunsumio-for-people-with-relapsed-or-refractory-follicular-lymphoma.html."},{"key":"e_1_3_1_61_1","unstructured":"FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma [Available from. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma."},{"key":"e_1_3_1_62_1","unstructured":"FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma [Available from. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma."},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179906"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7588"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.127"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185057"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_3_1_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00540-w"},{"key":"e_1_3_1_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804641"},{"key":"e_1_3_1_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853"},{"key":"e_1_3_1_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180762"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35114"},{"key":"e_1_3_1_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185038"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2024.2447371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T23:00:46Z","timestamp":1745794846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2024.2447371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,5]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4,16]]}},"alternative-id":["10.1080\/10428194.2024.2447371"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2024.2447371","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}